Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Joshua Reed, Senior Vice President and Chief Financial Officer of Alkermes plc (ticker ALKS), submitted an initial Form 3 reporting his relationship to the issuer and stating that no securities are beneficially owned as of the reported event date. The filing cites the event date of 09/15/2025 and is signed on behalf of Mr. Reed by an attorney-in-fact, Shantale Greenson, on 09/23/2025. The form includes an exhibit listing a Power of Attorney (Exhibit 24.1) and contains standard Section 16(a) reporting information without disclosure of any direct or indirect holdings or derivative positions.
Joshua Reed, Senior Vice President and Chief Financial Officer of Alkermes plc (ticker ALKS), submitted an initial Form 3 reporting his relationship to the issuer and stating that no securities are beneficially owned as of the reported event date. The filing cites the event date of 09/15/2025 and is signed on behalf of Mr. Reed by an attorney-in-fact, Shantale Greenson, on 09/23/2025. The form includes an exhibit listing a Power of Attorney (Exhibit 24.1) and contains standard Section 16(a) reporting information without disclosure of any direct or indirect holdings or derivative positions.
Alkermes plc furnished an update related to its narcolepsy program. The company issued a press release detailing safety and efficacy results from Vibrance-1, its phase 2 study of alixorexton (formerly ALKS 2680) versus placebo in patients with narcolepsy type 1. The update coincides with Alkermes’ participation at the World Sleep Congress held September 5–10, 2025.
The press release, an investor presentation and scientific presentations are included as exhibits and are incorporated by reference, but the information is being furnished under Regulation FD rather than filed for liability purposes. This 8-K does not itself include numerical trial results, but directs investors to the accompanying materials for detailed clinical data.
T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 shares of Alkermes plc common stock, representing 6.1% of the class as of June 30, 2025. The firm reports sole voting power for 9,983,207 shares and sole dispositive power for 10,041,900 shares on a Schedule 13G/A.
The filing identifies T. Rowe Price as an investment adviser filing under Rule 13d-1(b) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The Schedule is signed by Ellen York, Vice President, dated August 14, 2025.
Alkermes (ALKS) Q2-25 10-Q highlights: Net revenue slipped 2% YoY to $390.7 m as a 36% fall in manufacturing & royalty income (-$46.4 m) outweighed a 14% jump in proprietary product sales to $307.2 m. VIVITROL +9% to $121.7 m, ARISTADA franchise +18% to $101.3 m and LYBALVI +18% to $84.3 m.
Earnings & cash: Operating income from continuing ops declined 15% to $93.0 m; diluted EPS fell to $0.52 from $0.55. R&D spending rose 30% to $77.4 m while SG&A was flat. Lower royalties cut gross margin mix but cost-of-goods remained modest at 12.7% of sales. Operating cash flow rose 49% to $249.0 m, lifting cash & equivalents to $521.2 m (vs $291.1 m YE-24); no long-term debt remains, eliminating interest expense.
Balance sheet: Total assets grew to $2.25 bn; equity improved 11% to $1.62 bn. Share count fell 2% YoY to 165.1 m; $200 m of the $400 m buyback authorization is still available.
Key developments: • Royalty stream from long-acting INVEGA products continued to fade after August-24 U.S. expiry. • Medicaid rebate true-ups cut reserves by $30.1 m, aiding cash. • July-25 settlement with Zydus grants first generic VUMERITY entry only immediately prior to patent expiry. • New U.S. patent (12,311,027) extends ARISTADA protection to 2033.
Outlook: Management signals further revenue mix shift toward proprietary brands, higher R&D for pipeline assets (e.g., alixorexton), and materially higher operating cash following recent U.S. tax law changes.